Cardiorespiratory exercise testing before and during lung cancer treatment
Assessment of Respiratory Parameters and Physical Performance in Patients With Lung Cancer Qualified for Oncological Treatment Before and During Therapy, With Special Consideration of Cardiovascular Risk: A Cardiopulmonary Exercise Testing Study
This project tests whether a supervised exercise test (CPET) can measure heart and lung fitness in adults with lung cancer who are able to exercise (WHO/ECOG 0-2) before and during their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Bialystok Academic / other |
| Locations | 1 site (Bialystok, Podlaskie Voivodeship) |
| Trial ID | NCT07529145 on ClinicalTrials.gov |
What this trial studies
This prospective observational project enrolls adults with histologically confirmed lung cancer who are planned for standard oncological management and can perform exercise. Participants undergo a supervised cardiopulmonary exercise test (CPET) before treatment start and again after the early phase of therapy or surgery to measure VO2peak, ventilatory efficiency, and integrated cardiorespiratory responses. All oncological treatments follow routine clinical care and CPET is the only study-specific procedure. The study is conducted at a tertiary university hospital in Bialystok with planned enrollment of about 90 consecutive patients.
Who should consider this trial
Good fit: Adults (≥18) with histologically confirmed lung cancer of any stage who are scheduled for standard surgical or systemic treatment and have WHO/ECOG performance status 0–2 and the ability to perform CPET.
Not a fit: Patients with unstable cardiac disease, severe uncontrolled respiratory problems, resting oxygen saturation ≤85%, or any condition preventing safe exercise are excluded and unlikely to benefit from CPET here.
Why it matters
Potential benefit: If successful, CPET could identify patients with low physiological reserve so clinicians can tailor monitoring and supportive care to reduce treatment complications.
How similar studies have performed: Similar CPET approaches have been used and shown predictive value for surgical risk and treatment tolerance, though prospective data across the course of standard oncological therapy are relatively limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed lung cancer (any stage) * Qualified for standard oncological management (surgery and/or systemic therapy) * WHO/ECOG performance status 0-2 * Ability to perform cardiopulmonary exercise testing (CPET) * Written informed consent Exclusion Criteria: * Unstable ischemic heart disease * Symptomatic cardiac arrhythmias * Myocarditis or pericarditis * Decompensated heart failure * Active deep vein thrombosis * Suspected aortic dissection or severe aortic stenosis * Poorly controlled asthma * Resting oxygen saturation ≤ 85% on room air * Clinically relevant treatment-related adverse events above mild intensity (as applicable) * Any medical condition that, in the investigator's opinion, precludes safe participation in CPET * Withdrawal of informed consent
Where this trial is running
Bialystok, Podlaskie Voivodeship
- University Clinical Hospital in Bialystok, II Department of Pulmonology, Lung Cancer and Internal Medicine, Medical University of Bialystok — Bialystok, Podlaskie Voivodeship, Poland (Recruiting)
Study contacts
- Study coordinator: Klaudia Jadczak, Medical Doctor
- Email: klaudia.jadczak@sd.umb.edu.pl
- Phone: +48608726832
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.